|

Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis

RECRUITINGSponsored by Medical University of Lublin
Actively Recruiting
SponsorMedical University of Lublin
Started2019-09-01
Est. completion2024-05-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06440148

Summary

Mastocytosis is very rare and highly heterogeneous group of disorders, characterized by the accumulation of clonal mast cells which can infiltrate several organs and tissues. Bones are the most frequent localization of systemic mastocytosis. The aim of our research was to explain the potential role of sclerostin in the pathogenesis of bone disease in mastocytosis.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age \> 18 years
* Mastocytosis defined according to WHO criteria
* Known KIT mutation status

Exclusion Criteria:

* History of organ transplant
* Inability to give informed consent
* Pregnancy, Breastfeeding
* Vulnerable Patient, defined as: patient with another uncontrolled severe disease; patient under juridical protection

Conditions3

BonesCancerMastocytosis

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.